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Abstract
Background—The accuracy of EUS in the locoregional assessment of ampullary lesions is 
unclear.
Objectives—To compare EUS with ERCP and surgical pathology for the evaluation of 
intraductal extension and local staging of ampullary lesions.
Design—Retrospective cohort study.
Setting—Tertiary-care referral center.
Patients—All patients who underwent EUS primarily for the evaluation of an ampullary lesion 
between 1998 and 2012.
Intervention—EUS.
Main Outcome Measurements—Comparison of EUS sensitivity/specificity for intraductal 
and local extension with ERCP and surgical pathology by using the area under the receiver-
operating characteristic (AUROC) curves and outcomes of the subgroup referred for endoscopic 
papillectomy.
Results—We identified 119 patients who underwent EUS for an ampullary lesion, of whom 99 
(83%) had an adenoma or adenocarcinoma. Compared with ERCP (n = 90), the sensitivity/
specificity of EUS for any intraductal extension was 56%/97% (AUROC = 0.77; 95% confidence 
interval [CI], 0.64-0.89). However, when using surgical pathology as the reference (n = 102), the 
sensitivity/specificity of EUS (80%/93%; AUROC = 0.87; 95% CI, 0.76-0.97) and ERCP (83%/
93%; AUROC = 0.88; 95% CI, 0.77-0.99) were comparable. The overall accuracy of EUS for 
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local staging was 90%. Of 58 patients referred for endoscopic papillectomy, complete resection 
was achieved in 53 (91%); in those having intraductal extension by EUS or ERCP, complete 
resection was achieved in 4 of 5 (80%) and 4 of 7 (57%), respectively.
Limitation—Retrospective design.
Conclusions—EUS and ERCP perform similarly in evaluating intraductal extension of 
ampullary adenomas. Additionally, EUS is accurate in T-staging ampullary adenocarcinomas. 
Future prospective studies should evaluate whether EUS can identify characteristics of ampullary 
lesions that appropriately direct patients to endoscopic or surgical resection. (Gastrointest Endosc 
2015;81:380-8.)
The diagnostic approach to suspected ampullary tumors remains controversial. For 
ampullary adenomas, endoscopic resection is preferred over surgery given its lower 
morbidity.1 However, some patients will undergo incomplete endoscopic resection in the 
setting of occult adeno-carcinoma, often caused by invasion of the duodenum, pancreas/
pancreatic duct (PD), or bile duct (BD).2-4 A previous prospective study of 106 patients with 
a benign tumor of the major or minor papilla treated endoscopically reported intraductal 
extension significantly reduced the likelihood of complete endoscopic resection from 83% to 
46% (P< .001).3 In our recent cohort study of individuals undergoing endoscopic 
papillectomy, patients with incomplete resection had a significantly higher rate of 
intraductal extension (as defined by ERCP) than those with complete resection (31.3% vs 
9.0%; P = .0002).2 EUS is a less-invasive alternative to ERCP for the local staging of 
ampullary lesions. Although intraductal extension is not an absolute contraindication to 
endoscopic resection, EUS findings of intraductal extension or duodenal/pancreas invasion 
may triage patients to nonendoscopic treatment modalities and minimize the likelihood of 
incomplete endoscopic resection.5-9
Because of a paucity of evidence, the American Society for Gastrointestinal Endoscopy 
guideline recommends using EUS on a case-by-case basis in the workup of ampullary 
lesions.9 In a prospective trial of patients with ampullary lesions (n = 40), surgical resection 
was avoided in 10 patients (25%) who underwent EUS and intraductal US.5 Of those 
referred for endoscopic papillectomy (n = 10), all (7 with adenoma and 3 with 
adenocarcinoma limited to the mucosal layer) underwent successful endoscopic resection. 
Although several studies showed the reliability of EUS for T staging of ampullary 
neoplasms, these were limited by small sample size, heterogeneity of study design 
(combining both duodenal and ampullary lesions), or limited comparative analysis of 
intraductal extension with ERCP and surgical pathology.5,8,10
Our primary objective was to compare EUS with ERCP and surgical pathology for the 
locoregional evaluation of ampullary lesions. Specifically, we measured the rates of 
intraductal extension and local tissue invasion by using surgical pathology as the reference 
standard. The secondary objectives were to describe the impact of intraductal extension 
(defined by EUS, ERCP, or both) on endoscopic resectability and the performance 
characteristics of EUS-FNA in this setting. Although there are subtle histopathological 
differences between a lesion arising from the duodenal aspect of the major papilla and one 
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arising from within the ampulla, we use the terms ampulla and papilla interchangeably and 
papillectomy to describe the endoscopic resection technique.
METHODS
Study population
By using an endoscopy database (ProVationMD; Wolters Kluwer Health, Philadelphia, Pa), 
we identified all patients who were referred for EUS to evaluate a known or suspected 
ampullary lesion (a previous biopsy suggesting adenoma/adenocarcinoma) between January 
1998 and December 2012. Patients who had a previous ERCP with or without biliary stent 
placement were excluded from the study. Lesions were categorized as adenomatous (ranging 
from adenoma to adenocarcinoma) and nonadenomatous. We abstracted medical records for 
relevant demographic and clinical data, including the following lesion characteristics: 
intraductal (BD or PD) extension, local tissue (duodenum, pancreas, other) invasion, and 
size (by endoscopy, EUS, and surgical pathology). We describe each patient's management 
after EUS, including endoscopic or surgical resection and medical treatment. The accuracy 
of tumor staging, intraductal extension, and histo-logical features were evaluated by using 
surgical pathology as the reference standard. Our local institutional review board approved 
the study protocol before the collection of data.
EUS examination
All EUS examinations were performed before deciding to proceed with endoscopic or 
surgical resection (or neither). All patients underwent EUS with the absence of an overlying 
biliary stent. The indications for EUS included characterizing the tumor, locoregional 
staging (the assessment of intraductal extension and local tissue invasion), and/or obtaining 
a tissue diagnosis. All EUS procedures were performed by 1 of 6 experienced 
endosonographers (J.L., S.S., J.D., M.A., L.M., or G.C.) and ERCP by 1 of 6 experienced 
providers in ERCP (S.S., E.F., L.M., G.C., J.W., or G.L.), 3 of whom also performed EUS. 
During the examination, EUS was routinely completed to assess (1) tumor depth, (2) 
invasion into local structures (duodenum and/ or pancreas), (3) intraductal extension (BD, 
PD, or both), and (4) involvement of regional lymph nodes (LNs). The decisions to perform 
CT or magnetic resonance imaging before EUS or to perform FNA during the procedure 
were left to the discretion of the treating physician. EUS was performed by using radial 
echoendoscopes (GFUM20, GF-UM130, or GF-UM160; Olympus America, Inc, Center 
Valley, Pa) and/or linear echoendoscopes (32UA or 32 UX; Pentax Medical Co, Montvale, 
NJ or GF-UC30P or GF-UC140P; Olympus America, Inc). In some cases, FNA was 
performed by using a 19- or 22-gauge needle (Cook Endoscopy, Winston-Salem, NC) with 
the presence of on-site cytopathology.
Post-EUS management
After EUS, a therapeutic decision to proceed with endoscopic or surgical resection or to 
refer to medical oncology was made by the treating physician/endosonographer. Pre-
resection sampling histopathology (mucosal biopsies) was performed at the discretion of the 
referring physician/endoscopist. Indications influencing the decision to proceed with ERCP 
included 1 or more of the following: (1) ampullary lesions without invasion of the 
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muscularis propria and considered potentially amenable to endoscopic papillectomy, (2) 
patients planned for surgical removal who had elevated bilirubin and/or alkaline phosphatase 
levels necessitating preoperative biliary drainage, or (3) poor surgical candidates requiring 
palliative biliary stent placement. During ERCP, performing endoscopic papillectomy was 
determined based on underlying medical comorbidities and the following lesion 
characteristics: (1) no or limited (<1 cm) intraductal extension, (2) no invasion of the 
muscularis propria, (3) no lymph node involvement, and (4) no distant metastasis. 
Endoscopic removal was performed by using a side-viewing duodeno-scope with a 
therapeutic (4.2 mm) working channel (Olympus Optical Co, Tokyo, Japan). At the time of 
endoscopic resection, intraductal extension (BD, PD, or both) was also assessed. When 
feasible, the lesion was resected en bloc by using an electrocautery snare with alternating 
cut/coagulation current (ERBO-TOM 200 HF; ERBE USA, Marietta, Ga).2 Otherwise, a 
piecemeal resection technique was used.11 If residual adenomatous tissue was suspected 
after resection, the endoscopist attempted to ablate it by using electrocautery or argon 
plasma coagulation.
For patients who did not meet the indications for endoscopic papillectomy, they were 
referred for surgical or medical oncology consultation as appropriate. For those proceeding 
to resection (surgical or endoscopic), the procedure occurred on the same day or within 2 
weeks of the diagnostic EUS.
Definitions
At the time of EUS, an ampullary tumor was identified as an iso- or hypoechoic mass 
emerging from the ampulla of Vater. Locoregional staging included the evaluation of 
intraductal extension and local tissue invasion. Intraductal extension was defined as a 
discrete lesion in the BD (Fig. 1) or PD arising from the primary tumor. Local tissue 
invasion was described with the TNM classification system: no evidence of primary tumor 
(T0), carcinoma in situ (Tis), limited to the ampulla of Vater or sphincter of Oddi (T1), 
invasion of the duodenal muscularis propria/duodenal wall (T2), invasion of the pancreas 
(T3), invasion of the peripancreatic soft tissues or other adjacent organs or structures other 
than the pancreas (T4).12 Because the American Society for Gastrointestinal Endoscopy 
guideline (2006) recommended performing ERCP with both BD and PD evaluation at the 
time of endoscopic resection to assess for evidence of extension into either ductal system,9 
we compared EUS with ERCP by using ERCP as the reference standard for the evaluation 
of intraductal extension. During cholangiopancreatography (balloon-occluded technique), 
intraductal extension was defined by extension of a polypoid-filling defect into the BD or 
PD or tumor protruding from the ductal orifice with impaired contrast flow through the 
duodenal lumen (Fig. 2). For patients undergoing EUSFNA of the primary lesion, 
cytopathology was reported as adenoma, atypia, adenocarcinoma, or normal duodenal tissue. 
For those having EUS-FNA of a regional LN, cyto-pathology was reported as reactive LN or 
metastatic adenocarcinoma.
Preoperative evaluations by EUS and ERCP were compared with surgical pathology, which 
was the reference standard. Final surgical pathology included adenoma, advanced adenoma 
(defined as tubulovillous adenoma, villous adenoma, or adenoma with high-grade 
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dysplasia), adenocarcinoma, and all others. Of those undergoing endoscopic papillectomy of 
an ampullary adenoma, we assumed no intraductal extension if the lesion was completely 
removed with a negative margin reported by surgical pathology and no ductal extension 
identified during cholangiography. Moreover, we defined complete resection as a patient 
who underwent at least 1 surveillance endoscopy with no endoscopic evidence of residual 
adenoma. For patients who underwent surgical resection, intraductal extension was defined 
by its presence on surgical pathology. We defined complete surgical resection as a patient 
who underwent surgical removal with a negative tumor margin on histopathology.
Statistical analysis
We compared the performance characteristics (sensitivity/specificity) of EUS for intraductal 
(BD, PD, or both) and local staging with ERCP and surgical pathology (reference standard) 
by using area under the receiver-operating characteristic (AUROC) curves with 95% 
confidence intervals (CIs). We also analyzed outcomes from the subgroup referred for 
endoscopic papillectomy. Variables are presented as actual numbers and proportions. 
Statistical analyses were performed by using Stata version 11.2 (StataCorp LP, College 
Station, Tex).
RESULTS
Patient characteristics
During the 15-year study period, we identified 119 patients (59 female; mean age, 67.1 ± 
14.5 years) who underwent EUS primarily for the evaluation of an ampullary lesion (Fig. 3). 
ERCP was performed in 90 patients (76%). Clinical presentations included incidental 
findings (n = 36; 30%), screening for familial adenomatous polyposis) (n = 8; 7%), elevated 
liver or pancreas chemistries (n = 15; 13%), and overt symptoms (acute pancreatitis, 
abdominal pain, or jaundice) (n = 60; 50%). By endoscopy, EUS, and pathology, median 
lesion size was 20 mm (range 10-60 mm), 18 mm (range 8-50 mm), and 18 mm (range 4-78 
mm), respectively. Based on histopathology, 20 (17%) were nonadenomatous. The 
remaining (n = 99) included adenoma (n = 31; 26%), advanced adenoma (n = 33; 28%), and 
adenocarcinoma (n = 35; 29%). Of those with an adenomatous lesion, 6 were lost to follow-
up after EUS.
Therapeutic management after EUS
After EUS, a total of the 113 patients with ampullary tumors underwent surgery (n = 39), 
endoscopic papillectomy (n = 58), systemic therapy (n = 5), or endoscopic surveillance/no 
follow-up (n = 11) (Fig. 3). All patients with adenoma/adenocarcinoma who underwent 
surgery (n = 36) had a negative tumor margin, 28 (78%) had no intraductal extension, and 8 
(22%) had intraductal extension. Endoscopic papillectomy was performed in 48 
adenomatous lesions (48%) and 10 nonadenomatous lesions (50%).
EUS for the assessment of intraductal extension
In the subgroup of individuals who underwent ERCP (n = 90), we compared detection rates 
of intraductal extension when using EUS and ERCP (Table 1). With ERCP as the reference, 
the sensitivity, specificity, and accuracy of EUS for any intraductal extension were 56%, 
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97%, and 90%, respectively (AUROC = 0.77; 95% CI, 0.64-0.89). The majority of 
discordance was in BD extension seen on ERCP but not on EUS (6/12); however, in those 
having no EUS but only ERCP evidence of BD extension (n = 6), surgical pathology of the 
resected specimen and EUS agreed on no BD extension in 4 of 6.
In the subgroup of individuals who underwent endoscopic (n = 58) or surgical (n = 39) 
resection, we compared EUS and ERCP with surgical pathology for intraductal extension 
(Tables 2 and 3). With surgical pathology as the reference (n = 81), the sensitivity, 
specificity, and accuracy of ERCP for any intraductal extension were 83%, 93%, and 84%, 
respectively (AUROC = 0.88; 95% CI, 0.77-0.99) (Table 2). Comparable to ERCP, the 
sensitivity, specificity, and accuracy of EUS (n = 102) for intraductal extension were 80%, 
93%, and 91%, respectively (AUROC = 0.87; 95% CI, 0.76-0.97) (Table 3). Intraductal 
extension was incorrectly classified in 13 of 81 patients by ERCP and in 9 of 102 patients by 
EUS.
Based on the type of echoendoscopes, EUS was performed by using a radial alone in 92 
patients, linear alone in 21, and both in 6. When surgical pathology was used as the 
reference, the accuracy of radial and linear echoendoscopes was comparable. The accuracy 
of using a radial echoendoscope (n = 75) was 8 of 10 (80%) and 62 of 65 (95%) in 
classifying the presence and absence of intraductal extension, respectively. The accuracy of 
using a linear echoendoscope (n = 21) was 4 of 4 (100%) and 16 of 17 (94%) in determining 
the presence and absence of intraductal extension, respectively. Intraductal extension was 
incorrectly identified in 5 of 75 by radial echoendo-scopes and in 1 of 21 by linear 
echoendoscopes.
EUS for the assessment of local tissue invasion
For the assessment of local tissue invasion, the overall accuracy of EUS was 90% by using 
surgical pathology as the reference standard (Table 4). The accuracy of EUS was 98%, 78%, 
80%, and 78% in identifying patients with T1, T2, T3, and T4 stages, respectively. Of 
lesions confined to the ampulla (n = 66), EUS incorrectly described invasion of the pancreas 
in 1. In all others (n = 34), 7 patients having invasion of the duodenal wall (n = 4), pancreas 
(n = 1), and other structures (n = 2) found in the surgical specimens were missed by EUS; 1 
patient was triaged inappropriately to endoscopic removal, whereas 6 patients were triaged 
correctly to surgery because of adenocarcinoma found in the biopsy specimen (n = 4) and 
positive cytology for malignancy (n = 2).
Outcomes of endoscopic papillectomy after EUS examination
Of 90 patients proceeding to ERCP after EUS, endoscopic papillectomy was performed in 
58; preoperative biliary drainage was performed in 27 and palliative drainage in 5. In those 
undergoing endoscopic papillectomy (n = 58), jaundice was present in 5 (9%). Other 
presentations included incidental findings (n = 25; 43%), familial adenomatous polyposis 
screening (n = 3; 5%), abnormal laboratory test results (n = 6; 10%), and overt symptoms (n 
= 24; 41%). By endoscopy, EUS, and pathology, the median size of these lesions was 15 
mm (range 10-50 mm), 16 mm (range 9-50 mm), and 15 mm (6-50 mm), respectively. 
Based on surgical pathology of the resected specimens, 10 were found to have a 
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nonadenomatous lesion (despite a previous biopsy specimen suggesting adenoma; these 
samples were not reviewed by histopathology at our institution before endoscopic 
papillectomy); carcinoid tumor (n = 1), ectopic gastric mucosa (n = 1), fibro-muscular 
dysplasia (n = 1), hyperplastic polyp (n = 2), normal duodenal mucosa (n = 2), and chronic 
inflammation (n = 3). No intraductal invasion was identified in nonadenomatous lesions. 
The remaining included adenoma (n = 25; 43%), advanced adenoma (n = 21; 36%), and 
adenocarcinoma (n = 2; 3%). We identified intraductal extension by EUS in 5 (9%) by 
ERCP in 7 (12%). EUS and ERCP agreed on no intraductal extension in 50 and intraductal 
involvement in 5. There were 3 discordant cases, with intraductal extension seen by EUS 
only in 1 and ERCP only in 2; complete endoscopic resection was achieved in 2 of these 3 
cases.
Complete endoscopic resection with a negative surveil-lance endoscopy occurred in 53 of 58 
(91%); in those having intraductal extension suggested by EUS and ERCP, complete 
resection was achieved in 4 of 5 (80%) and 4 of 7 (57%), respectively. Two patients with 
incomplete resection were found to have intraductal invasion at ERCP (confirmed by 
surgical specimens), which were missed by EUS. In the remaining 3 cases (advanced 
adenoma [n = 2] and adenocarcinoma [n = 1]), EUS underestimated duodenal muscularis 
propria invasion that was proved by surgical pathology.
EUS-FNA in a cohort of individuals with ampullary adenocarcinoma
A total of 20 patients underwent FNA at the time of EUS. Of those, 16 underwent FNA of 
the ampullary lesion and 4 of a regional LN. Of those having FNA performed of the primary 
lesion, 4 were ultimately proved to have nonadenomatous lesions; EUS-FNA confirmed 
carcinoid in 1 and true negative (no malignancy or adenoma) in 3. The remaining included 
adenoma (n = 2), advanced adenoma (n = 3), and adenocarcinoma (n = 7) based on surgical 
pathology. EUS-FNA confirmed adenocarcinoma in 6 of 7 (86%) and adenoma/advanced 
adenoma in 1 of 5 (20%). Of those undergoing EUS-FNA of a regional LN, 3 were 
described as reactive LNs and 1 was reported as metastatic adenocarcinoma; all had 
adenocarcinoma with LN involvement (n = 2) and no LN involvement (n = 2) confirmed by 
surgical pathology.
DISCUSSION
Local staging of ampullary lesions when using EUS
Because of its lower morbidity compared with surgery, endoscopic papillectomy is the 
preferred technique for resection of precancerous lesions of the ampulla.1 Before endoscopic 
resection, recognition of adenocarcinoma (often missed with forceps biopsies of the 
ampulla), duodenal wall invasion, or extension of adenomatous tissue into the bile or 
pancreatic duct may influence the endoscopist's decision to proceed with endoscopic 
papillectomy. Given the inherent risks of ERCP and endoscopic papillectomy, incomplete 
endoscopic resection should be minimized. Therefore, accurate local staging of ampullary 
lesions is essential for the appropriate triage of patients to endoscopic or surgical resection. 
Previous studies showed that EUS is superior to transabdominal US, CT, and magnetic 
resonance imaging in assessing the T stage of ampullary lesions.13-19 In a recent meta-
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analysis that included 14 studies and 422 patients, the pooled sensitivity/specificity of EUS 
for diagnosing T1-stage tumor was 77%/78%.20 In our cohort (n = 119) of individuals being 
referred for consideration of endoscopic papillectomy, we observed an overall accuracy of 
90% compared with surgical pathology. This higher rate may be attributed to the absence of 
an overlying biliary stent. Because EUS is operator dependent, the accuracy may be superior 
when performed by higher volume endosonographers. The greatest accuracy of EUS was in 
identifying patients with T1 disease (98%). For T2, T3, and T4 lesions, the diagnostic 
accuracy decreased to 78%, 80%, and 78%, respectively.
Intraductal extension (<1 cm) of ampullary lesions
Although not a contraindication to endoscopic resection, intraductal extension is a 
significant risk factor for incomplete endoscopic resection (odds ratio 0.29, P = .01).2 A 
smaller Japanese series that included patients referred for surgery (n = 30) and endoscopic 
papillectomy (n = 10) reported high agreement with surgical pathology for bile (88%) and 
pancreatic (90%) duct extension when using EUS and 90% with intraductal US.5 In our 
cohort, EUS had 90% accuracy compared with ERCP for the assessment of intraductal 
extension of ampullary tumors. Compared with surgical pathology (n = 102), EUS and 
ERCP had comparable agreement for the evaluation of intraductal extension (91% and 
84%). Of those having an incorrect diagnosis by ERCP (13/81) and EUS (9/102), ERCP was 
more likely to overstage intraductal extension than EUS (11/81, 13% vs 6/102, 6%).
What is the clinical significance of identifying intraductal extension when using EUS? We 
anecdotally observed a higher rate of complete endoscopic resection (91%) in the current 
series compared with our recent analysis (73%) that included all individuals undergoing 
endoscopic papillectomy, 39% of whom had undergone EUS before resection.2 Of 182 
patients undergoing endoscopic papillectomy for ampullary lesions in our previous study, 
111 proceeded directly to ERCP without EUS; 70% had complete resection.2 Patients with 
lesions deemed unresectable at the time of EUS or ERCP because of extensive (>1 cm) 
intraductal extension, invasion of the duodenal submucosa, or lymph node invasion were 
excluded from our previous study.2 In a limited number of patients undergoing EUS before 
endoscopic papillectomy (n = 71) in this study, EUS was performed at similar frequencies in 
both the complete and incomplete endoscopic resection group (40% vs 35%; P = .55). 
However, patients with incomplete resection had a significantly higher rate of intraductal 
extension as defined by ERCP in this cohort (31% vs 9%, P = .0002); if a subgroup of these 
individuals had not undergone endoscopic papillectomy based on the finding of intraductal 
extension by EUS, then the complete resection rate may have been higher. Of 5 patients 
having incomplete resection in the current study, intraductal extension was detected in 2, 
both of which were missed by EUS. On the other hand, among 19 individuals with 
intraductal extension by EUS, 5 of 19 proceeded to endoscopic resection and 12 of 19 to 
surgical resection (1/19 underwent systemic chemotherapy and 1/19 had endoscopic 
surveillance with no intervention), with a complete endoscopic resection rate of 80%. Based 
on our results, it may be reasonable to consider strengthening society guidelines that 
currently recommend EUS on a case-by-case basis in the workup of ampullary lesions. 
Although this study is limited by its retrospective design, EUS may have appropriately 
triaged some or all patients referred for surgical resection, thereby improving the observed 
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complete endoscopic resection rate (91%). Given its safety profile and relatively low cost, 
especially when performed in the same setting as ERCP, EUS may reduce the need for 
diagnostic ERCP and the incidence of incomplete endoscopic resection. Although 
endoscopic papillectomy may be feasible in cases with intraductal growth, the rate of 
complete resection is lower.3
After EUS, 15 patients underwent successful surgical resection without ERCP because of 
adenocarcinoma found in the biopsy specimen (n = 3), intraductal extension (n = 2), and 
invasion of duodenal wall (n = 7)/pancreas (n = 3) with intraductal extension. The remaining 
3 patients with incomplete endoscopic resection in this cohort had invasion of the duodenal 
muscularis propria, all which were missed by EUS. In previous series, EUS understaged 
invasion of the duodenal muscularis propria, ranging from 8% to 15%.5,10 Our observations 
suggest that EUS is more likely to understage ampullary lesions, perhaps due to missing 
focal invasion of the muscularis propria that is only identified by histopathological analysis 
of the resected specimen.
In addition, 10 patients undergoing endoscopic papillectomy in our study were found to 
have a nonadenomatous lesion based on surgical pathology of the resected specimen despite 
a previous biopsy specimen suggesting adenoma. However, those previous histopathology 
results were not re-reviewed at our institution before endoscopic removal. This suggests the 
need for re-reviewing histopathology results at a tertiary center before making a therapeutic 
decision.
EUS-FNA of ampullary lesions
The performance characteristics of EUS-FNA of periampullary cancers are well 
established21,22; there are limited data analyzing the sensitivity/specificity of EUS-FNA in 
cohorts of ampullary lesions that include adenomas. In a study of 35 ampullary lesions, 13 
of which were adenocarcinoma, the diagnostic accuracy was 89%.23 In our cohort that 
included 20 patients who underwent EUS-FNA of an ampullary lesion (n = 16) or regional 
LN (n = 4), the accuracy of EUS-FNA for diagnosing adenocarcinoma was 86% (n = 6); on 
the other hand, the accuracy of diagnosing adenoma/advanced adenoma was only 20% (n = 
1) in a limited number of cases. However, discerning adenoma from high-grade dysplasia is 
very difficult based on cytology alone.
Limitations
Our study is limited by its retrospective design and lack of predefined criteria for proceeding 
from EUS to endoscopic or surgical resection. The endoscopists used evidence of either 
limited (<1 cm) intraductal extension or no intraductal extension as an indication for 
endoscopic removal during the study period; this may lead to inconsistent criteria for 
surgical referral and influence treatment outcome of endoscopic resection. Although the 
exact length of intraductal extension was not documented, the extent of intraductal 
involvement was between subcentimeter to a maximum length of approximately 1 cm. 
These data represent a subset of ampullary tumors seen at our institution as some proceed 
directly to ERCP without EUS. Nevertheless, our high rate of complete endoscopic resection 
(91%) compared with that of historical series suggests that EUS may have appropriately 
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triaged a subgroup of patients to nonendoscopic treatment modalities, thereby avoiding the 
risks of ERCP and endoscopic papillectomy.
Summary
In conclusion, EUS has good agreement with ERCP and surgical pathology for the 
assessment of intraductal extension and local staging of ampullary lesions. In selected cases 
of local tissue invasion or intraductal extension identified by EUS, ERCP and attempts at 
endoscopic resection may be avoidable. Future studies should compare alternative imaging 
modalities such as EUS, intraductal US, and cholangioscopy, for assessing intraductal 
extension, as its presence significantly reduces the likelihood of complete endoscopic 
resection. Furthermore, our analysis suggests the need for a prospective, comparative 
effectiveness study to further evaluate the impact of EUS on minimizing ERCP and 
incomplete endoscopic resection of ampullary lesions.
Abbreviations
AUROC area under the receiver-operating characteristic
DB bile duct
CI confidence interval
LN lymph node
PD pancreatic duct
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Figure 1. 
Intraductal extension (arrowheads) of ampullary adenocarcinoma by EUS. CBD, common 
bile duct.
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Figure 2. 
Distal bile duct stricture (arrowheads) secondary to intraductal extension of ampullary 
lesion by ERCP.
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Figure 3. 
Patient cohort: EUS for ampullary lesions between 1998 and 2012.
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TABLE 1
Accuracy of EUS for the assessment of intraductal extension when using ERCP as the reference standard
Intraductal involvement by ERCP
Intraductal involvement by EUS None Bile duct Pancreatic duct Both ducts Total
None 72 6 0 1 79
Bile duct 0 6 0 0 6
Pancreatic duct 0 0 1 0 1
Both ducts 2 0 0 2 4
Overstaged by EUS 2/74 0/12 0/1 0/3 2/90
Understaged by EUS 0/74 6/12 0/1 1/3 7/90
Accuracy 72/74 6/12 1/1 2/3 81/90 (90%)
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TABLE 2
Accuracy of ERCP for the assessment of intraductal extension when using surgical pathology as the reference 
standard
Intraductal involvement by pathology
Intraductal involvement by ERCP None Bile duct Pancreatic duct Both ducts Total
None 64 1 0 1 66
Bile duct 5 7 0 0 12
Pancreatic duct 0 0 1 0 1
Both ducts 0 0 0 2 3
Overstaged 5/69 0/8 0/1 0/3 11/81
Understaged 0/69 1/8 0/1 1/3 2/81
Accuracy, n/n (%) 64/69 1/8 1/1 2/3 68/81 (84%)
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TABLE 3
Accuracy of EUS for the assessment of intraductal extension when using surgical pathology as the reference 
standard
Intraductal involvement by pathology
Intraductal involvement by EUS None Bile duct Pancreatic duct Both ducts Total
None 81 3 0 0 84
Bile duct 3 6 0 0 9
Pancreatic duct 0 0 1 0 1
Both ducts 3 0 0 5 8
Overstaged 6/87 0/9 0/1 0/5 6/102
Understaged 0/87 3/9 0/1 0/5 3/102
Accuracy, n/n (%) 81/87 6/9 1/1 5/5 93/102 (91%)
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TABLE 4
Local staging of ampullary lesions by EUS versus surgical pathology
Surgical stage
EUS stage No primary tumor Limited to ampulla Invasion of 
duodenal 
wall
Invasion of pancreas Invasion of 
other 
structures
Total
Limited to ampulla 2 65 4 0 1 72
Invasion of duodenal 
wall
0 0 14 1 1 16
Invasion of pancreas 0 1 0 4 0 5
Invasion of other 
structures
0 0 0 0 7 7
Overstaged 2/2 1/66 0/18 0/5 0/9 3/100
Understaged 0/2 0/66 4/18 1/5 2/9 7/100
Accuracy, n/n (%) 0/2 65/66 14/18 4/5 7/9 90/100 (90%)
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